Literature DB >> 13396275

Use of mecamylamine in the management of hypertension.

E G MCQUEEN, F H SMIRK.   

Abstract

Entities:  

Keywords:  AUTONOMIC DRUGS/therapeutic use; HYPERTENSION/therapy

Mesh：

Substances：

Year:  1957        PMID： 13396275      PMCID： PMC1974514          DOI： 10.1136/bmj.1.5016.422

Source DB:  PubMed          Journal:  Br Med J        ISSN： 0007-1447


× No keyword cloud information.
  3 in total

1.  The treatment of high blood pressure with hexamethonium iodide.

Authors:  P A RESTALL; F H SMIRK
Journal:  N Z Med J       Date:  1950-06

2.  Treatment of arterial hypertension by penta- and hexamethonium salts; based on 150 tests on hypertensives of varied aetiology and 53 patients treated for periods of two to fourteen months.

Authors:  F H SMIRK; K S ALSTAD
Journal:  Br Med J       Date:  1951-06-02

3.  Action of a new methonium compound in arterial hypertension; pentamethylene 1 : 5-bis-n-(n-methyl-pyrrolidinium) bitartrate (M. & B. 2050A).

Authors:  F H SMIRK
Journal:  Lancet       Date:  1953-03-07       Impact factor: 79.321
  3 in total
  5 in total

1.  Treatment of hypertension with pentolinium and mecamylamine.

Authors:  H T SEARS; P J SNOW; I B HOUSTON
Journal:  Br Med J       Date:  1959-02-21

2.  Excretion of mecamylamine after intravenous and oral administration.

Authors:  K D ALLANBY; J R TROUNCE
Journal:  Br Med J       Date:  1957-11-23

3.  An anti-nicotinic cognitive challenge model using mecamylamine in comparison with the anti-muscarinic cognitive challenge using scopolamine.

Authors:  Anne Catrien Baakman; Ricardo Alvarez-Jimenez; Robert Rissmann; Erica S Klaassen; Jasper Stevens; Sebastiaan C Goulooze; Jeroen C G den Burger; Eleonora L Swart; Joop M A van Gerven; Geert Jan Groeneveld
Journal:  Br J Clin Pharmacol       Date:  2017-04-08       Impact factor: 4.335

4.  Region-specific effects of N,N'-dodecane-1,12-diyl-bis-3-picolinium dibromide on nicotine-induced increase in extracellular dopamine in vivo.

Authors:  S Rahman; Z Zhang; R L Papke; P A Crooks; L P Dwoskin; M T Bardo
Journal:  Br J Pharmacol       Date:  2007-12-03       Impact factor: 8.739

5.  DEPRESSION OF THE VASOMOTOR CENTRE BY MECAMYLAMINE, INDEPENDENT OF ITS GANGLION-BLOCKING ACTIVITY.

Authors:  K P BHARGAVA; K N DHAWAN
Journal:  Br J Pharmacol Chemother       Date:  1963-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.